NCT05557565 is a Phase 2 clinical trial of QL1706 in Cervical Cancer, sponsored by Qilu Pharmaceutical Co., Ltd..

Who is sponsoring NCT05557565?

NCT05557565 is sponsored by Qilu Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05557565?

Interventions in NCT05557565: QL1706.

What condition does NCT05557565 study?

NCT05557565 studies Cervical Cancer.

Is NCT05557565 still recruiting?

NCT05557565 is currently status unknown. Last updated 28 September 2022.

Last reviewed 2022-09-28 · How we verify

NCT05557565

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Status unknown Phase 2 Last updated 28 September 2022

What this trial tests

Phase 2 trial testing QL1706 in Cervical Cancer in 150 participants. Status unknown.

Timeline

21 December 2021

Primary endpoint
30 October 2022

30 June 2023

Quick facts

Lead sponsor	Qilu Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	21 December 2021
Primary completion	30 October 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

QL1706 — full drug profile →

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Qilu Pharmaceutical Co., Ltd. — full company profile →

Who can join

18 and older, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and safety of QL1706 in patients with recurrent or metastatic cervical cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2025.
Crescioli S, Kaplon H, Wang L, Visweswaraiah J, et al · · 2025 · cited 87× · PMID 39711140 · DOI 10.1080/19420862.2024.2443538
Advances in cervical cancer: current insights and future directions.
Xu M, Cao C, Wu P, Huang X, et al · · 2025 · cited 55× · PMID 39611440 · DOI 10.1002/cac2.12629
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).
Huang L, Zhu H, Shi Y. · · 2025 · cited 3× · PMID 41310835 · DOI 10.1186/s13045-025-01734-x
Treatment of Pelvic Recurrence After Radiotherapy for Cervical Cancer.
Song Y, Zou K, Zou L. · · 2025 · PMID 41463185 · DOI 10.3390/cancers17243934

Verify or expand the search:

Other trials of QL1706

Trials testing the same drug.

NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07413601 — Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinu · Phase 2 · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
NCT06787183 — SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases · Phase 2 · recruiting
NCT07172217 — The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC · Phase 2 · not yet recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Qilu Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07511647 — A Phase 3 Clinical Study of QL2106 Injection · Phase 3 · not yet recruiting
NCT07467629 — QLS5212 for Participants With Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07455006 — Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients · Phase 3 · not yet recruiting
NCT07463573 — QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma · Phase 3 · not yet recruiting
NCT07444086 — QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05557565 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Pharmaceutical Co., Ltd.
Last refreshed: 28 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05557565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing